TILT is building a pipeline of innovative cancer immunotherapies targeted at treating solid tumors.
The power of TILT’s approach which enables its proprietary oncolytic viruses to be encoded with a variety of cytokines, means that it should have applicability across a wide range of cancer indications, including melanoma, head and neck cancer, and cancers of the ovary, lungs and pancreas.
- Product/Program: TILT-123; TILT-T115
- Indication: Solid Tumors (EU)
- Description: Phase 1 monotherapy safety for TILT-123
- Development status: Phase 1 trials; Helsinki University Hospital (Finland) and Docrates Cancer Centre (Finland)
- Product/Program: TILT-123; TILT-T215
- Indication: Melanoma (EU)
- Description: Monotherapy safety for TILT-123 and use with TILs
- Development Status: Phase 1 trials; Herlev (Denmark), Nantes (France).
- Product/Program: TILT-123; TILT-T563
- Indication: Ovarian cancer (USA and EU)
- Description: Collaboration with Merck MSD for the use of pembrolizumab (anti-PD-1)
- Development status: Phase 1 trials; Rochester (MN, USA), Docrates Cancer Centre (Finland)
- Product/Program: TILT-123; TILT-T776
- Indication: Solid Tumors (USA and EU)
- Description: Collaboration with Merck / Pfizer for the use of avelumab (anti-PD-L1)
- Development status: Phase 1 trials; New York City (NY, USA), Docrates Cancer Centre (Finland)
- Product/Program: TILT-123; TILT-T610
- Indication: Lung Cancer (US)
- Description: Collaboration with Merck MSD for the use of pembrolizumab (anti-PD-1)
- Development status: CMC/IND stage
-
TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human T- cell stimulating cytokines; TNF alpha and IL-2.
- Product: TILT-123
- Indication: Biotheus indications (CN)
- Description: License agreement with Biotheus
- Development status: Phase 1 trials: China
-
TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human T- cell stimulating cytokines; TNF alpha and IL-2.
- Product: TILT-234
- Indication: Solid tumors
- Description: Ready to enter CMC and regulatory studies. For systemic and intravenous use to enable Dendritic cell therapy. Available for out-licensing
- Development status: CMC/IND stage
-
TILT-234 structure: Based on Adenovirus serotype 3 (Ad3) genome that is armed with human CD40L.
- Product: TILT-452
- Indication: Solid Tumors
- Description: Local delivery of next generation payloads.
- Development status: Preclinical
-
TILT-452 structure: Ad5/3 with double selectivity for safety and for both systemic and intravenous use. Arming is specific for T-cell targeting.
- Product: TILT-321 and TILT-322
- Indication: Solid Tumors
- Description: T-cell recruitment into tumors and local activation. Local delivery of bispecific antibody (US patent No. 11485791)
- Development status: Discovery
-
TILT-321 structure: Ad5/3 coding for a bispecific antibody
Science
Our patented TILT® technology, based on oncolytic viral therapies, modifies the tumour microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T-cell therapies.
Partners
Our pioneering approach has been recognized by industry leaders including Germany’s Merck KGaA and the USA’s Pfizer (Merck-Pfizer Alliance), MSD International GmbH, and Biotheus, a privately held Chinese biotechnology company.